<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038673</url>
  </required_header>
  <id_info>
    <org_study_id>5878-CL-0101</org_study_id>
    <nct_id>NCT02038673</nct_id>
  </id_info>
  <brief_title>An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors</brief_title>
  <official_title>An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to determine the tolerability, safety, pharmacokinetics
      (PK), pharmacodynamics (PD), and efficacy of oral ASP5878 in patients with solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of two parts. In the dose-escalation part, ASP5878 (orally available
      novel small-molecule FGFR 1,2,3 and 4 inhibitor, multiple dosing once-a-day (q.d.), multiple
      dosing twice-a-day (b.i.d.) or 5-day on/2-day off dosing twice-a-day (5on-2off)) is
      administered to patients with solid tumors in an increasing dose manner, and the
      tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of ASP5878
      are evaluated in these patients. Cycle 0 consists of 3 days and Cycle 1 and subsequent cycles
      consist of 28 days each in the dose-escalation part. In the expansion part, 16mg twice-a-day
      5-day on/2-day off dose of ASP5878 (5on-2off) is administered to patients with solid tumors
      and safety, PK, PD and efficacy of ASP5878 are evaluated. The expansion part starts from
      Cycle 1 and each cycle consists of 28 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 5, 2013</start_date>
  <completion_date type="Actual">July 19, 2017</completion_date>
  <primary_completion_date type="Actual">July 19, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part: Safety assessed by Adverse Events (AEs)</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part:Safety assessed by Vital signs</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Blood pressure, pulse rate and body temperature, Until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part:Safety assessed by Body weight</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part:Safety assessed by Laboratory tests</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Hematology, blood biochemistry, blood coagulation tests and urinalysis, until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part:Safety assessed by 12-lead ECGs</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>ECG: Electrocardiogram, until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part: Ophthalmology</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Eyesight, funduscopy, slit lamp microscopy, and Optical Coherence Tomography, until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part: Bone density measurement</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-escalation part and Expansion part: Imaging study</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Expansion part only: Echocardiogram</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: Pharmacokinetics (PK) parameter of ASP5878 in plasma: Cmax</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>Cmax: Maximum concentration, Cycle 0: single dose, Cycle 1: multiple dose after Cycle 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part:PK parameter of ASP5878 in plasma: tmax</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>tmax: Time of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part:PK parameter of ASP5878 in plasma: AUClast</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>AUClast: Area under the concentration-time curve from the time of dosing extrapolated to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PK parameter of ASP5878 in plasma: AUCinf</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PK parameter of ASP5878 in plasma: t1/2</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PK parameter of ASP5878 in plasma: CL/F</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>CL/F: Apparent total systemic clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PK parameter of ASP5878 in plasma: Vz/F</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>Vz/F: Apparent volume of distribution during the terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PK parameter of ASP5878 in urine: Ae</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>Ae: Amount of ASP5878 excreted into the urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PK parameter of ASP5878 in urine: CLR</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>CLR: Renal clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: Pharmacodynamic (PD) parameter: Serum FGF23 concentrations</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>FGF: Fibroblast Growth Factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PD parameter: Serum inorganic phosphorus concentrations</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PD parameter: Serum calcium concentrations</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PD parameter: Serum iPTH concentrations</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
    <description>iPTH: Intact Parathyroid Hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-escalation part: PD parameter: Serum calcitriol concentrations</measure>
    <time_frame>Day 1 at Cycle 0 and Day 5 (5on-2off) or 27 (q.d./b.i.d.) at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: Cmax</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: tmax</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: AUClast</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: AUCinf</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: t1/2</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: CL/F</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PK parameter of ASP5878 in plasma: Vz/F</measure>
    <time_frame>Day 1 and 5 at Cycle 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PD parameter: Serum FGF19 concentrations</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PD parameter: Serum FGF23 concentrations</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PD parameter: Serum inorganic phosphorus concentrations</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PD parameter: Serum iPTH concentrations</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: PD parameter: Serum calcitriol concentrations</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Until one of the discontinuation criteria is met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expansion part: Antitumor activity evaluated based on RECIST</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>RECIST version 1.1, until one of the discontinuation criteria is met.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>dose escalation part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>expansion part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP5878</intervention_name>
    <description>oral</description>
    <arm_group_label>expansion part</arm_group_label>
    <arm_group_label>dose escalation part</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed solid tumor.

          -  Patient must meet at least one of the following criteria in the judgment of the
             investigator or sub-investigator:

               -  Disease progression despite standard therapies

               -  Progressive disease without any standard therapies established

               -  Standard therapies are considered intolerable

          -  Eastern Cooperative Oncology Group performance status 0 or 1.

          -  Predicted life expectancy ≥ 12 weeks in the judgment of the investigator or
             sub-investigator.

        Exclusion Criteria:

          -  Patient with ≥ Grade 2 (CTCAE v 4.0-JCOG) persistent symptoms and objective findings
             due to the toxicity attributable to prior treatment with antitumor effect (except
             alopecia).

          -  Patient who received a prior treatment intended for antitumor effect (medication,
             surgery, radiotherapy, etc.) within 4 weeks prior to the planned first day of study
             drug dosing (or patient who received mitomycin C or Nitrosourea within 6 weeks prior
             to the planned first day of study drug dosing).

          -  A major surgical procedure within 4 weeks prior to the planned first day of study drug
             dosing or a surgical procedure is planned during the course of the study.

          -  Patient who were treated with other investigational drug or medical device within 4
             weeks prior to the planned first day of study drug dosing.

          -  Patient who has a history of organ transplantation.

          -  Patient with a brain metastasis with symptoms or requiring treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site US402</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US401</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US404</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US406</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US410</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US403</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP122</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP108</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP115</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP120</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP116</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP113</name>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP103</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP111</name>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP119</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP101</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP109</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP110</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP112</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP117</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP121</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP104</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP106</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP118</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP124</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP102</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP107</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site JP123</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR202</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR201</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR203</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site KR204</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW302</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW301</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site TW303</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Afghanistan</country>
  </removed_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2014</study_first_submitted>
  <study_first_submitted_qc>January 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP5878</keyword>
  <keyword>FGFR 1,2,3 and 4 inhibitor</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

